Selumetinib

Overview

Selumetinib, also known as AZD6244, is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, and so may inhibit cellular proliferation in MEK-overexpressing tumor cells. MEK 1 and 2 are dual-specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various tumor cell types, and are drivers of diverse cellular activities, including cellular proliferation. Check for active clinical trials or closed clinical trials using this agent.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | MEK

Product Information

• Catalog No.: B0084-095434
• CAS No.: 606143-52-6
• Molecular Formula: C17H15BrClFN4O3
• Molecular Weight: 457.684
• Purity: >98%
• Storage: 2 - 8 °C

Source

Original product source